Occurrence of HLA- and non-HLA antibodies after heart transplantation are associated with cardiac allograft vasculopathy

Chronodiagnostical methods for evaluating reserve and unfavourable responses of human cardiac function and under prolonged stress load.

The paper offers an analysis of activation therapy approaches to an increase in efficacy of antitumor treatment with the use…

The results of study of an artificial aortic valve by the heart cycle phase analysis are given in the paper.…

Monitoring the health of astronauts based on the assessment of the functional state of the body within the realms of…

Original research

Occurrence of HLA- and non-HLA antibodies after heart transplantation are associated with cardiac allograft vasculopathy

Maja-Theresa Dieterlen1Jens Garbade1Robert Riede1Stefan Dhein1Friedrich W. Mohr1Hartmuth B. Bittner2Markus J. Barten1*

1 University of Leipzig, Department of Cardiac Surgery, Heart Center, 04289 Leipzig, Germany
2 Florida Hospital Orlando, Department Cardiothoracic Transplantation and Advanced Cardiac Surgery, Orlando, Florida, USA

* Corresponding author:
   +49 (341) 865-14-21
  This email address is being protected from spambots. You need JavaScript enabled to view it.

Aims

Cardiac allograft vasculopathy (CAV) accounts for major morbidity and mortality late in the heart transplant (HTx) history. The role of antibodies (Abs) directed against human leukocyte antigens (HLA) and non-HLA antigens in the pathogenesis of CAV are still under investigation.

Materials and methods

Sera of 116 long-term HTx recipients with CAV (n=46) and without CAV (n=70) were analysed by (1) Luminex for Abs against both HLA classes and major histocompatibility complex class I-related chain A (MICA), and by (2) ELISA for Abs against angiotensin-type-1-receptor (AT1R) or endothelin-receptor-A (ETAR). Cellular rejection by endomyocardial biopsies and immunosuppressive drug therapy were analysed, too.

Results

HTx recipients developed higher levels of non-HLA-Abs than of Abs against HLA. CAV appeared more frequently in recipients with non-HLA-Abs (38.3% AT1R; 44.1% ETAR; 13.0% MICA) than in recipients with HLA-Abs (8.7% HLA class I; 8.7% HLA class II). Recipients with non-HLA-Abs developed CAV earlier (73.7±47.4months) than recipients without Abs (85.5±50.6months).

Conclusion

Occurrence of HLA-Abs and non-HLA-Abs contribute to CAV after HTx. Non-HLA-Abs were connected to an earlier and higher incidence of CAV. Recipients with subclinical cellular rejections and AT1R-Abs and ETAR-Abs as well as recipients with certain donor specific-Abs again HLA and MICA specifities are at risk to develop CAV.

Imprint

Maja-Theresa Dieterlen, Jens Garbade, Robert Riede, Stefan Dhein, Friedrich W. Mohr, Hartmuth B. Bittner, Markus J. Barten. Occurrence of HLA- and non-HLA antibodies after heart transplantation are associated with cardiac allograft vasculopathy; Cardiometry; No.4; May 2014; p.71-85; DOI:10.12710/cardiometry.2014.4.7185 Available from: http://www.cardiometry.net/no4-may-2014/cardiac-allograft-vasculopathy

Keywords

UPCOMING ISSUE

Our book in WoS™ Core Collection

We are glad to inform you that the book "Theoretical principles of heart cycle phase analysis" written by researchers from Russian New University has been accepted and indexed in The Book Citation Index in Web of Science™ Core Collection

VIDEO ABOUT CARDIOMETRY

OUR PARTNERS

Russian New University


Your online partner for English language editing, proofreading, medical writing, formatting, design & development and publication support services